Health and Fitness, is important to living a healthy life. Learn the newest research from our Press Releases today.
-Un estudio confirma que la frecuencia de donación de Source Plasma según lo regula la FDA de EE.UU. no perjudica la salud y el bienestar del donante ANNAPOLIS, Md., 26 de agosto de 2023 /PRNewswire/ — La Plasma Protein Therapeutics Association (PPTA) anunció la publicación de su estudio…
DUBLIN, Aug. 25, 2023 /PRNewswire/ — The “Gene Fusion Testing Market – A Global and Regional Analysis: Focus on by Category, Technology, Indication, End User, and Region – Analysis and Forecast, 2023-2033” report has been added to ResearchAndMarkets.com’s offering. The global gene fusion…
Nectar Hex Bests the Market in Temperature, Charging Time & Heat-Up Time
LONDON, Aug. 25, 2023 /PRNewswire-PRWeb/ — Nectar, the UK’s leading dry herb vaporizer brand, aims to disrupt the dry herb vape market with a groundbreaking new device that combines a patented rapid hybrid heating system and a luxurious, hygienic 24ct gold chamber. The Nectar Hex utilizes both convection and conduction to produce a vapor with superior flavor in less than 20 seconds.
“The Nectar Hex is innovation that advances our mission to provide the healthiest means of responsibly enjoying and utilizing nature’s medicines,” said Mario, Director at Nectar. “Every aspect of the revolutionary Nectar Hex was designed and built with our customers in mind. Nectar is again setting the gold standard for the dry herb vaping experience.”
Dry herb vaping allows users to get the full benefits of cannabis without inhaling toxic, potentially carcinogenic fumes created during traditional smoking methods. Heating the herb rather than burning it also provides enhanced flavors. “The Nectar Hex’s patented heating system allows for better flavor, consistent vapor, more precise temperature control and fast vapor production,” said Mario. “Our customers can customize their vaping experience with precision temperature control and with the Hex’s airflow slider.”
Other advanced features of the Nectar Hex include:
“We’re working to remove the stigma associated with dry herbs,” said Mario. “Nectar Hex features like the MagStick Multi Use Tool and ability to store three spare filters in the battery compartment enable help customers to enjoy dry herb vaping conveniently and discretely.”
The Nectar Hex Basic Kit includes a Nectar Hex Vaporizer, a USB-C Fast Charging Cable, a Cleaning Kit, a Dosing Capsule for herbs and a Dosing Capsule for extracts, three gauze pads and two Isopropyl alcohol pads. The Nectar Hex is available from Nectar and Amazon.
ABOUT NECTAR
Nectar Medical Vapes is an e-commerce company based in London, United Kingdom. Nectar was founded with the sole purpose of providing the healthiest means of responsibly enjoying and utilizing nature’s medicines through the use of hardware such as vaporizers, whilst completely avoiding the consumption of toxins and carcinogens. Nectar products are becoming increasingly popular and are setting themselves as a gold standard in product quality and is currently the UK’s leading dry herb vaporizer brand.
Media Contact
Adrienne Uthe, Kronus Communications, 1 7154181614, [email protected], https://kronuscommunications.com/
SOURCE Nectar Medical Vapes
KYOTO, Japan, 25. August 2023 /PRNewswire/ — OMRON Healthcare Co., Ltd. (im Folgenden als das Unternehmen bezeichnet) mit Sitz in Muko, Präfektur Kyoto, hat das offizielle Sponsoring des European Society of Cardiology Congress 2023 (im Folgenden als ESC Congress 2023 bezeichnet) durch…
Proper refrigeration is a vital aspect of various sectors, from safeguarding the freshness of food in restaurants to maintaining the efficacy of vaccines in medical laboratories. The need to comply with local, state, and federal regulations concerning temperature monitoring has further accentuated the importance of precise and consistent temperature management. Three new reporting tools now address the multiple industry requirements:
Refrigeration Monitoring Package
The newly launched reports are included as part of the Swift Sensors Refrigeration Monitoring Package – a startup bundle that packages sensors, a gateway, temperature buffers, and the software to get up and running quickly with the system. It offers a seamless integration of advanced technology with user-friendly features, making it suitable for multiple industries:
Restaurant Chains, Casinos, and Resorts
With this system, Executive Chefs can receive instant alerts if temperatures fall outside the safe range for food storage, ensuring food quality and safety. Learn more about Swift Sensors Restaurant Temperature Monitoring Systems.
School Food Services
Nutrition Managers and Food Service Directors can now have peace of mind, knowing that children’s lunches are stored at the correct temperatures, thanks to Swift Sensors’ precise monitoring. Review solutions for School Cafeteria Temperature Monitoring.
Medical Labs
By maintaining optimal temperatures for vaccines, medicines, and test trials, Swift Sensors’ system plays an essential role in healthcare efficiency and effectiveness. View systems for Medical Lab Temperature Monitoring.
Manufacturing Companies
Whether it’s inventory or specific cold storage areas, the refrigeration monitoring system assures that everything is stored at the desired temperatures, supporting seamless operations. Click here to see the Manufacturing Refrigeration Monitoring system we offer for industrial applications.
Unparalleled Features
The core value of Swift Sensors’ refrigeration monitoring system lies in its real-time alert system. Instant notifications via email, text message, and phone calls ensure that all stakeholders are promptly informed if there are any temperature inconsistencies. Moreover, the system’s ability to create automated logs of temperatures ensures compliance with regulations and provides a transparent record of operations.
CEO’s Statement
‘The Internet of Things (IoT) has grown from science fiction to a basic requirement for protecting equipment, facilities, and business processes across a wide range of industries. Our built-in reports not only satisfy regulatory requirements for governing bodies such as state and local health inspectors, they also automate daily logging – freeing up valuable staff resources to focus on more important tasks. We are excited to package these new reporting capabilities with high-quality measurement sensors and easy-to-use software for use across so many different applications.’
Availability and Support
The Refrigeration Monitoring System is available for purchase directly through Swift Sensors and authorized distributors. Comprehensive support and guidance are provided, ensuring a smooth integration of the system into existing operations.
About Swift Sensors
Swift Sensors is a leading wireless sensor company specializing in cutting-edge monitoring solutions. With a reputation for innovation, quality, and reliability, Swift Sensors has become a trusted name among top organizations. The introduction of the Refrigeration Monitoring System is yet another milestone in the company’s continuous pursuit of excellence.
For more information about the Refrigeration Monitoring System or any other offerings from Swift Sensors, please visit https://www.swiftsensors.com/ or contact [email protected].
Media Contact
Jason Duncan, Swift Sensors, 1 512-256-7552, [email protected], https://www.swiftsensors.com/
SOURCE Swift Sensors
This sandwich ELISA is designed with polyclonal antibodies coated onto the plate for capturing ANNEXIN A1 (ANXA1) in the tested sample.
A5D-55902 5-ELISA Annexin A1 Antigen click here for more information
The entire Aniara product line is available for purchase at http://www.aniara.com. The Company distributes products in North America, Sweden, Norway, Denmark, Finland, Lithuania, Latvia, Estonia and Iceland.
Media Contact
Maria Waldron, Aniara Diagnostica, 513-342-3018, [email protected], www.aniara.com
SOURCE Aniara Diagnostica
“This report demonstrates that the evidence-based Embark Behavioral Health treatment approach is effective for decreasing anxiety, depression, and distress associated with the high rates of suicide while increasing healthy development and well-being,” said Embark Behavioral Health Chief Clinical Officer Dr. Rob Gent, who has a doctorate in psychology. “This report additionally highlights the use of validated measurement tools and surveys to not only measure progress over time but also to accurately inform treatment in real time to optimize clients’ results, which is a key differentiator of Embark.”
The outcomes report offers a plethora of valuable data about how Embark is helping its clients and their families heal.
Suicide Risk
Upon admission in 2022, 52% of clients reported some thoughts of suicide. At discharge, the average client reported no thoughts of suicide.
Long-Term Residential Treatment
Long-term residential clients and parents reported a high level of improvement in daily functioning and lower distress. They indicated similar progress for anxiety and depression symptoms. Specific findings include:
Short-Term Residential Treatment
Short-term residential clients saw an immediate improvement in anxiety, depression, overall functioning, and relationships. Specific findings include:
Outpatient Therapy
Data from outpatient clinics indicate strong improvements in behavioral functioning, distress, anxiety, depression, and well-being. Specific findings include:
Future Research Directions
Moving forward, Embark will continue researching post-discharge treatment effectiveness for up to two years after treatment. To improve holistic health, the company is examining the relationship between several biological functions (sleep, nutrition, exercise, and heart rate variability) and relational and emotional health. The goal is to contribute to the scientific understanding of how these functions can improve overall well-being.
For more information on treatment options and the Embark Behavioral Health continuum of care offered for preteens, teens, and young adults, visit embarkbh.com.
ABOUT EMBARK BEHAVIORAL HEALTH
Embark Behavioral Health is a leading network of outpatient centers and residential programs offering premier mental health treatment for preteens, teens, and young adults. Dedicated to its big mission of reversing the trends of teen and young adult anxiety, depression, and suicide by 2028, Embark offers a robust continuum of care with different levels of service and programming; has a deep legacy of over 25 years serving youths; works with families to adjust treatment in real time to improve results; treats the entire family using an evidence-based approach; and offers the highest levels of quality care and safety standards. For more information about Embark or its treatment programs, including virtual services, intensive outpatient programs (IOPs), therapeutic day treatment programs, also known as partial hospitalization programs (PHPs), residential treatment, and outdoor therapy, visit http://www.embarkbh.com.
Media Contact
Madison Breuer, Serendipit Consulting, 6022835209, [email protected], https://serendipitconsulting.com/
SOURCE Embark Behavioral Health
The addition of Dr. Ann Korkidakis to Boston IVF and its Massachusetts fertility centers in Worcester and Waltham bolsters the availability of prompt reproductive care for individuals aspiring to create a family.
WALTHAM, Mass., Aug. 22, 2023 /PRNewswire-PRWeb/ — Boston IVF, one of the world’s most experienced fertility treatment providers, which has assisted in over 150,000 babies born since 1986, is pleased to announce that reproductive endocrinologist, Ann Korkidakis, MD has joined its practice and physician team.
Dr. Korkidakis is now accepting new patients at all of Boston IVF’s fertility centers in Massachusetts via telemedicine and in person at the Worcester and Waltham, Massachusetts locations. She specializes in a comprehensive array of infertility treatments and family building services, including, intrauterine insemination (IUI), in vitro fertilization (IVF), egg freezing, LGBTQ+ family building services, recurrent pregnancy loss, PCOS, and more.
Her current research interests include early embryo development, recurrent pregnancy loss, and ongoing barriers to fertility care.
A native of Montreal, Quebec – she is fluent in French and Greek.
Alongside her role as a fertility doctor, Dr. Korkidakis is a member of the American Society for Reproductive Medicine (ASRM), the New England Fertility Society (NEFS), the Pacific Coast Reproductive Society (PCRS), the Canadian Fertility and Andrology Society (CFAS), and the American College of Obstetricians and Gynecologists (ACOG).
“As a former reproductive fellow at Beth Israel Deaconess Medical Center and Boston IVF – we know firsthand the talent and expertise that Dr. Korkidakis brings to our Boston IVF fertility treatment team and are thrilled to have her join us.,” said David Stern, CEO of Boston IVF.
The Beth Israel Deaconess Medical Center/Boston IVF Reproductive Endocrinology and Infertility (REI) Fellowship program is amongst the most prestigious and intensive in the world, equipping fertility doctors with superior training, research, and empathy to help their patients build a family through assisted reproductive technology.
“To join Boston IVF and have the unique opportunity to work alongside such esteemed mentors is truly a great honor,” said Ann Korkidakis, MD. “I look forward to continuing in my role as a trusted resource for my patients in Waltham, Worcester, and across the state of Massachusetts.”
Double-board certified in OB/GYN and REI, Dr. Korkidakis earned her medical degree at McGill University, completed her residency in Obstetrics and Gynecology at Queen’s University, and received her fellowship in Reproductive Endocrinology at both the University of British Columbia in Vancouver and Beth Israel Deaconess Medical Center/Harvard Medical School in conjunction with Boston IVF.
Boston IVF’s Waltham Fertility Center offers a full array of reproductive treatment and care, including on-site andrology and embryology (IVF) laboratories, blood and ultrasound cycle monitoring, male infertility testing, IUI, IVF, egg freezing, and more.
Boston IVF’s Worcester Fertility Center offers a variety of services, including consultations, intrauterine inseminations (IUI), semen analysis, and blood/ultrasound monitoring.
To learn more about Dr. Korkidakis, to receive fertility treatment advice, or to schedule a consultation, visit Boston IVF’s website.
Follow Boston IVF on Instagram
ABOUT BOSTON IVF
Boston IVF is one of the largest and most experienced fertility networks in the United States, with more than 150,000 babies born since 1986. Founded as one of the nation’s first private practice IVF centers, the Boston IVF network has grown to include over 30 reproductive endocrinologists across 30 centers throughout Massachusetts, Maine, Massachusetts, Rhode Island, New York, Delaware, Idaho, Indiana, North Carolina, Ohio, and Utah. A renowned innovator of reproductive technologies, advanced protocols, and cutting-edge research, Boston IVF has achieved numerous “firsts” in reproductive care. Its scientific and research arm continues to pave the way for breakthroughs in fertility care and its accredited REI Fellowship Program has graduated numerous reproductive endocrinologists as part of its mission to train the next generation of fertility experts.
Media Contact
Zoe Marzi, Boston IVF, 1 781-434-6515, [email protected], https://www.bostonivf.com/
Theo Lopreste, Boston IVF, 1 781-434-6451, [email protected], https://www.bostonivf.com/
SOURCE Boston IVF
The Rigicon ContiClassic® is a new sphincteric device designed to treat male stress urinary incontinence. This study evaluates the surgical outcomes and safety profile of the first 116 patients who received the implant between September 2021 and April 2022.
RONKONKOMA, N.Y., Aug. 23, 2023 /PRNewswire-PRWeb/ — Rigicon, Inc. a leading global innovator of prosthetic urology devices and solutions based in NY proudly announces the recent publication of “First safety outcomes for Rigicon ContiClassic®: Artificial Urinary Sphincter.” The results of the study show the safety outcomes for the Rigicon ContiClassic® to be comparable to others presently on the market which underscores the transformative potential of the Rigicon ContiClassic® in evolving the treatment landscape for male stress urinary incontinence.
Discover more: https://www.nature.com/articles/s41443-023-00748-8
The Rigicon ContiClassic® Artificial Urinary Sphincter is the newest device for treating stress urinary incontinence (SUI) in men and was introduced worldwide two years ago with the first case being implanted in September 2021. The study, meticulously conducted from September 2021 to April 2022, delved into the experiences of the initial 116 patients who underwent the Rigicon ContiClassic® implant procedure. The results arising from this thorough evaluation underline the device’s effectiveness and safety, instilling optimism among those dealing with SUI.
With an in-depth analysis of patient demographics, surgical intricacies, and underlying causes of incontinence, the Rigicon ContiClassic® showcased remarkable efficacy across a diverse patient cohort. Notably, the study’s participants boasted a mean age of 68.3 years, with urinary incontinence post-radical prostatectomy emerging as the predominant reason (58.6%) for implantation. Encouragingly, the study reported no instances of infections or grave complications. A standout highlight of the study was the Kaplan-Meier calculation, unveiling an impressive survival rate of 93.2% at the 12-month juncture.
With a direct quote from the publication, “The ContiClassic® features a hydrophilic coating on all components which allows for antibiotics of the surgeon’s choice to be adsorbed onto the device’s surface for elution into the implant spaces. The connectors of ContiClassic® do not require an assembly tool, and the cuff sizes have smaller increments in diameter (0.25 cm rather than 0.5 cm). An attractive enhancement of the ContiClassic® to the original AMS 800 design involves making the pump of much softer silicone that makes deactivation and activation of the pump much easier for both the physician and the patient. It is hoped this will allow physicians to easily teach their patients nightly deactivation while sleeping.”
Prof. Steven K. Wilson, a renowned authority in urology, lauded the study’s findings, stating, “The Rigicon ContiClassic® signifies a key moment in addressing male stress urinary incontinence. Its combination of innovative design and promising safety outcomes makes it a surefire choice for patients seeking effective solutions.”
Rigicon’s pursuit of excellence in medical device innovation is underlined by the Rigicon ContiClassic®, ready to reshape the narrative surrounding in male stress urinary incontinence treatment.
Rigicon is a global leader in prosthetic urology with products currently available in over 50 countries. A full list of products can be found on the company’s website at www.rigicon.com. Rigicon stands at the forefront of medical innovation, driven by a commitment to enhancing patient care and quality of life. Rigicon ContiClassic® reinforces the company’s dedication to groundbreaking solutions that redefine medical possibilities.
About Rigicon
Rigicon, based in Ronkonkoma, NY, is a pioneering company specializing in the design, development, and manufacturing of innovative urology devices. Our mission is to enhance the quality of patient care with our world-class products, which are developed in close collaboration with top surgeons worldwide. We remain committed to our mission to provide solutions that improve the quality of life for patients around the globe.
Media Contact
Jessica Miranda, Rigicon, Inc., 1 88820290, [email protected], www.rigicon.com
SOURCE Rigicon, Inc.
FARMINGTON, Conn., Aug. 23, 2023 /PRNewswire/ — BroadcastMed, the leading healthcare marketplace that provides trusted clinical content, powerful engagement and industry insights to healthcare professionals, medical institutions and manufacturers, service providers, and pharmaceutical…
